https://orcid.org/0000-0001-9054-9379
Citations (120)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
David Johnson, Lanxuan Feng & Charlotte Johnson. (2023) Retrospective review of the efficacy for sublingual ketamine in the treatment of chronic low back pain defined by a cause and central functional pain symptom focused clinical model. Disability and Rehabilitation 0:0, pages 1-8.
Read now
Read now
Brian N. Corwell, Sergey M. Motov, Natalie L. Davis & Hong K. Kim. (2022) Novel uses of ketamine in the emergency department. Expert Opinion on Drug Safety 21:8, pages 1009-1025.
Read now
Read now
Anees Bahji, Carlos A. Zarate & Gustavo H. Vazquez. (2022) Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert Opinion on Drug Safety 21:6, pages 853-866.
Read now
Read now
Jan Van Amsterdam & Wim Van Den Brink. (2022) Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. Expert Opinion on Drug Safety 21:1, pages 83-94.
Read now
Read now
Mitch Earleywine, Brianna R. Altman & Joseph De Leo. (2022) Cognitive Behavioral Therapy, Ketamine, and Combination Treatment for Depression: Impressions of Credibility in Participants with Self-Reported Depressive Symptoms. Journal of Psychoactive Drugs 54:1, pages 70-80.
Read now
Read now
Kirsten C Morley, Christina J Perry, Joshua Watt, Tristan Hurzeler, Lorenzo Leggio, Andrew J Lawrence & Paul Haber. (2021) New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. Expert Opinion on Pharmacotherapy 22:10, pages 1291-1303.
Read now
Read now
Justin Reinert & Brittany L. Parmentier. (2021) Effect of Perioperative Ketamine on Postoperative Mood and Depression: A Review of the Literature. Expert Review of Clinical Pharmacology 14:1, pages 25-32.
Read now
Read now
Articles from other publishers (113)
Li-Juan Zhu, Fei Li & Dong-Ya Zhu. (2023) nNOS and Neurological, Neuropsychiatric Disorders: A 20-Year Story. Neuroscience Bulletin 39:9, pages 1439-1453.
Crossref
Crossref
Emily Whinkin, Therry Rose J. Eparwa, Michelle C. Julseth, Andrea Schneider & Sunil K. Aggarwal. (2023) Reductions in anxiety and depression symptoms in a subset of outpatients with problematic substance use who received ketamine-assisted psychotherapy: a two-year retrospective chart review. Frontiers in Psychiatry 14.
Crossref
Crossref
Ümmühan Kandemir. (2023) Etiopathogenesis of depression and experimental depression models used in preclinical studies. European Journal of Life Sciences 2:2, pages 78-90.
Crossref
Crossref
Jennifer M. Mitchell & Brian T. Anderson. (2023) Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. Neuropsychopharmacology.
Crossref
Crossref
Mikhail Y. Popov, Olga V. Lepik, Vladimir L. Kozlovskii & Yuri V. Popov. (2023) Pharmacological strategies for appetite modulation in eating disorders: a narrative review. Consortium Psychiatricum 4:2, pages 79-90.
Crossref
Crossref
Mengmeng Zhang, Xiangru Kong, Jing Chen, Wenqin Liu, Can Liu, Xiaoyun Dou, Lin Jiang, Yanmin Luo, Mingrui Song, Peng Miao, Yong Tang & Yun Xiu. (2023) Dysfunction of GluN3A subunit is involved in depression-like behaviors through synaptic deficits. Journal of Affective Disorders 332, pages 72-82.
Crossref
Crossref
Karolina Podkowa, Kamil Czarnacki, Agnieszka Borończyk, Michał Borończyk & Justyna Paprocka. (2023) The NMDA receptor antagonists memantine and ketamine as anti-migraine agents. Naunyn-Schmiedeberg's Archives of Pharmacology 396:7, pages 1371-1398.
Crossref
Crossref
Nicholas David Richards, William Weatherhead, Simon Howell, Mark Bellamy & Ruben Mujica-Mota. (2023) Continuous infusion ketamine for sedation of mechanically ventilated adults in the intensive care unit: A scoping review. Journal of the Intensive Care Society.
Crossref
Crossref
Rayyan Zafar, Maxim Siegel, Rebecca Harding, Tommaso Barba, Claudio Agnorelli, Shayam Suseelan, Leor Roseman, Matthew Wall, David John Nutt & David Erritzoe. (2023) Psychedelic therapy in the treatment of addiction: the past, present and future. Frontiers in Psychiatry 14.
Crossref
Crossref
Gen Li, Binshi Bo, Puxin Wang, Peixing Qian, Mingzhe Li, Yuyan Li, Chuanjun Tong, Kaiwei Zhang, Baogui Zhang, Tianzi Jiang, Zhifeng Liang & Xiaojie Duan. (2023) Instantaneous antidepressant effect of lateral habenula deep brain stimulation in rats studied with functional MRI. eLife 12.
Crossref
Crossref
Sharma Meha, Satish Suhas & Naren P Rao. (2023) Successful use of ketamine to treat severe depression with suicidality post-COVID-19 – A case report. Psychiatry Research Case Reports 2:1, pages 100100.
Crossref
Crossref
Cinthia Cristina Menezes da Silveira, Sabrina de Carvalho Cartágenes, Natália Harumi Corrêa Kobayashi, Sarah Viana Farias, Fábio José Coelho de Souza-Junior, Luanna Melo Pereira Fernandes, Alejandro Ferraz do Prado, Walessa Alana Bragança Aragão, Rafael Rodrigues Lima, Wallax Augusto Silva Ferreira, Edivaldo Herculano Correa de Oliveira, Fernando Augusto Rodrigues Mello Júnior, Rommel Mario Rodríguez Burbano, Enéas Andrade Fontes-Júnior & Cristiane do Socorro Ferraz Maia. (2023) One binge-type cycle of alcohol plus ketamine exposure induces emotional-like disorders associated with oxidative damage in adolescent female rats. Biomedicine & Pharmacotherapy 162, pages 114641.
Crossref
Crossref
Sina Dehestani, Amir Houshang Mohammadpour, Seyed Alireza Sadjadi, Thozhukat Sathyapalan & Amirhossein Sahebkar. (2023) Clinical use of ketamine in psychiatric disorders. Annales Médico-psychologiques, revue psychiatrique 181:6, pages 495-508.
Crossref
Crossref
Marco Antônio Pinto Coutinho, Thyerre Castro Coelho & Christian Diniz Lima e Silva. (2023) O USO DE ANTIDEPRESSIVOS E O RISCO AUMENTADO DE SUICÍDIO/AUTOCÍDIO: uma revisão de literatura. Psicologia e Saúde em Debate 9:1, pages 309-321.
Crossref
Crossref
Hai-Xia Chang, Wei Dai, Jin-Hao Bao, Jin-Feng Li, Ji-Guo Zhang & Yun-Feng Li. (2023) Essential role of microglia in the fast antidepressant action of ketamine and hypidone hydrochloride (YL-0919). Frontiers in Pharmacology 14.
Crossref
Crossref
Bess M. Kew, Richard J. Porter, Katie M. Douglas, Paul Glue, Charlotte L. Mentzel & Ben Beaglehole. (2023) Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review. BJPsych Open 9:3.
Crossref
Crossref
Matthew R. Irwin, Carlos M. Curay, Shinbe Choi & Eugene A. Kiyatkin. (2023) Basic metabolic and vascular effects of ketamine and its interaction with fentanyl. Neuropharmacology 228, pages 109465.
Crossref
Crossref
O. Damri, S. Natour, S. Asslih & G. Agam. (2023) Does treatment with autophagy-enhancers and/or ROS-scavengers alleviate behavioral and neurochemical consequences of low-dose rotenone-induced mild mitochondrial dysfunction in mice?. Molecular Psychiatry 28:4, pages 1667-1678.
Crossref
Crossref
Shinnosuke Yasugaki, Hibiki Okamura, Ami Kaneko & Yu Hayashi. (2023) Bidirectional relationship between sleep and depression. Neuroscience Research.
Crossref
Crossref
Samara J. Brown, Amelia M. Brown, Tertia D. Purves-Tyson, Xu-Feng Huang, Cynthia Shannon Weickert & Kelly A. Newell. (2023) GRIN2B gene expression is increased in the anterior cingulate cortex in major depression. Journal of Psychiatric Research 160, pages 204-209.
Crossref
Crossref
Lauren E. Gatewood, Andrew W. Gorlin, Christopher H. Bailey, George Barsoum & Steven B. Porter. (2023) A Pain Physician and Anesthesiologist’s Perspective on Ketamine for Treatment-Resistant Depression. SN Comprehensive Clinical Medicine 5:1.
Crossref
Crossref
Yu Qin, Xinlei Guo, Wenyue Song, Zehuai Liang, Yahui Wang, Dan Feng, Yiru Yang, Mingxing Li & Mingqi Gao. (2023) Antidepressant-like effect of CP-101,606: Evidence of mTOR pathway activation. Molecular and Cellular Neuroscience 124, pages 103821.
Crossref
Crossref
Hao-Yue Li, Meng-Li Tian, Chen-Lin Wang, Jin-Feng Zhou, Zi-Gui Wang, Wen Zhang, Xue-Jie Qi & LiLi Duan. (2023) A novel Thermo-responsive hydrogel system (THS) loaded with the active ingredient of Gardenia jasminoides J. Ellis exhibits anti-depressant effects in vivo via intranasal administration. Journal of Drug Delivery Science and Technology 81, pages 104223.
Crossref
Crossref
Katarzyna Stachowicz. (2023) The role of polyunsaturated fatty acids in neuronal signaling in depression and cognitive processes. Archives of Biochemistry and Biophysics 737, pages 109555.
Crossref
Crossref
Tzu-Hsin Huang, Ming-Chi Lai, Yu-Shiue Chen & Chin-Wei Huang. (2023) The Roles of Glutamate Receptors and Their Antagonists in Status Epilepticus, Refractory Status Epilepticus, and Super-Refractory Status Epilepticus. Biomedicines 11:3, pages 686.
Crossref
Crossref
Yu-Jung Cheng, Chieh-Hsin Lin & Hsien-Yuan Lane. (2023) Ketamine, benzoate, and sarcosine for treating depression. Neuropharmacology 223, pages 109351.
Crossref
Crossref
Huan Ren, Fengmei Lin, Lifang Wu, Lina Tan, Lili Lu, Xiuli Xie, Yang Zhang, Yanni Bao, Yuchen Ma, Xiaoqin Huang, Fang Wang & Yong Jin. (2023) The prevalence and the effect of interferon -γ in the comorbidity of rheumatoid arthritis and depression. Behavioural Brain Research 439, pages 114237.
Crossref
Crossref
Aurora Leontina Lombardi, Lucia Manfredi & David Conversi. (2023) How does IL-6 change after combined treatment in MDD patients? A systematic review. Brain, Behavior, & Immunity - Health 27, pages 100579.
Crossref
Crossref
Giordano Novak Rossi, Jaime E. C. Hallak, Glen Baker, Serdar M. Dursun & Rafael G. dos Santos. (2022) The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials. European Archives of Psychiatry and Clinical Neuroscience 273:1, pages 129-155.
Crossref
Crossref
Francisco Donoso, John F. Cryan, Loreto Olavarría‐Ramírez, Yvonne M. Nolan & Gerard Clarke. (2022) Inflammation, Lifestyle Factors, and the Microbiome‐Gut‐Brain Axis: Relevance to Depression and Antidepressant Action. Clinical Pharmacology & Therapeutics 113:2, pages 246-259.
Crossref
Crossref
Gulnar Mangat & Vivek K. Moitra. 2023. Evidence-Based Practice of Anesthesiology. Evidence-Based Practice of Anesthesiology
204
216
.
Heyang Zhang, Shuirong Liu, Qiaozhen Qin, Zhenhua Xu, Yannv Qu, Yadi Wang, Jianing Wang, Zhangzhen Du, Shanshan Yuan, Shunming Hong, Zhilin Chang, Wenyan He, Xinlong Yan, Yiran Lang, Rongyu Tang, Yan Wang, Lingling Zhu & Xiaoxia Jiang. (2022) Genetic and Pharmacological Inhibition of Astrocytic Mysm1 Alleviates Depressive‐Like Disorders by Promoting ATP Production. Advanced Science 10:1.
Crossref
Crossref
Shuo Wang, Chun-Mei Deng, Yuan Zeng, Jia-Hui Ma, Yuan Qu & Dong-Xin Wang. (2022) Single low-dose ketamine infusion for women with prenatal depressive symptoms undergoing cesarean delivery: A pilot randomized trial. Frontiers in Surgery 9.
Crossref
Crossref
Ayse Hande Arpacı, Hasan Çalıskan, Emel Gunes & Berrin Işık. (2022) Effects of the Recurrent and Different Doses of Ketamine Exposure on
Anxiety-like Behaviors and Locomotor Activity in Juvenile Rats. Current Alzheimer Research 19:14, pages 933-942.
Crossref
Crossref
Abhishek R. Giri, Nirmaljot Kaur, Siva Naga S. Yarrarapu, Kathleen A. Rottman Pietrzak, Christan Santos, Philip E. Lowman, Shehzad Niaz, Pablo Moreno Franco & Devang K. Sanghavi. (2022) “Novel Management of Depression Using Ketamine in the Intensive Care Unit”. Journal of Intensive Care Medicine 37:12, pages 1654-1661.
Crossref
Crossref
Marvin S. Meiering, David Weigner, Matti Gärtner, Thomas Schäfer & Simone Grimm. (2022) Does route of administration affect antidepressant efficacy of ketamine? A meta-analysis of double-blind randomized controlled trials comparing intravenous and intranasal administration. Journal of Psychiatric Research 156, pages 639-646.
Crossref
Crossref
Daniel R. George, Ryan Hanson, Darryl Wilkinson & Albert Garcia-Romeu. (2021) Ancient Roots of Today’s Emerging Renaissance in Psychedelic Medicine. Culture, Medicine, and Psychiatry 46:4, pages 890-903.
Crossref
Crossref
Matej Ľupták, Zdeněk Fišar & Jana Hroudová. (2022) Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism—In Vitro Study. International Journal of Molecular Sciences 23:22, pages 13824.
Crossref
Crossref
Shakila Meshkat, Joshua D. Rosenblat, Roger C. Ho, Taeho Greg Rhee, Bing Cao, Felicia Ceban, Kevork Danayan, Noah Chisamore, Joshua D.Di Vincenzo & Roger S. McIntyre. (2022) Ketamine use in pediatric depression: A systematic review. Psychiatry Research 317, pages 114911.
Crossref
Crossref
Xiaohui Zhou, Peipei Si, Li Wang & Huiqun Jia. (2022) Dexmedetomidine Regulates the miR-146a-5p/NF-κB Axis to Alleviate Electroconvulsive Therapy-Induced Cognitive Impairments. Computational and Mathematical Methods in Medicine 2022, pages 1-8.
Crossref
Crossref
Vishal Bharmauria, Afef Ouelhazi, Rudy Lussiez & Stéphane Molotchnikoff. (2022) Adaptation-induced plasticity in the sensory cortex. Journal of Neurophysiology 128:4, pages 946-962.
Crossref
Crossref
Tahani K. Alshammari, Sarah Alseraye, Nouf M. Alrasheed, Anfal F. Bin Dayel, Asma S. Alonazi, Jawza F. Al Sabhan & Musaad A. Alshammari. 2022. Ketamine Revisited - New Insights into NMDA Inhibitors. Ketamine Revisited - New Insights into NMDA Inhibitors.
Agnieszka Mechlińska, Adam Włodarczyk, Marta Gruchała-Niedoszytko, Sylwia Małgorzewicz & Wiesław Jerzy Cubała. (2022) Dietary Patterns of Treatment–Resistant Depression Patients. Nutrients 14:18, pages 3766.
Crossref
Crossref
Simon Zhornitsky, Valérie Tourjman, Julie Pelletier, Roxane Assaf, Chiang-Shan R. Li & Stéphane Potvin. (2022) Acute effects of ketamine and esketamine on cognition in healthy subjects: A meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 118, pages 110575.
Crossref
Crossref
Jiaxi Xie, Cailing Zhong, Tingting Wang, Dan He, Luyang Lu, Jie Yang, Ziyi Yuan & Jingqing Zhang. (2022) Better Bioactivity, Cerebral Metabolism and Pharmacokinetics of Natural Medicine and Its Advanced Version. Frontiers in Pharmacology 13.
Crossref
Crossref
Miguel Pérez de la Mora, Dasiel O. Borroto-Escuela, Minerva Crespo-Ramírez, José del Carmen Rejón-Orantes, Daniel Alejandro Palacios-Lagunas, Magda K. Martínez-Mata, Daniela Sánchez-Luna, Emiliano Tesoro-Cruz & Kjell Fuxe. (2022) Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders. Cells 11:11, pages 1826.
Crossref
Crossref
Qi Li, Dong-Na Zhou, Yi-Qing Tu, Xin-Wei Wu, Da-Qing Pei & Yun Xiong. (2022) Ketamine administration ameliorates anesthesia and surgery‑induced cognitive dysfunction via activation of TRPV4 channel opening. Experimental and Therapeutic Medicine 24:1.
Crossref
Crossref
Tien-Wei Hsu, Che-Sheng Chu, Pao-Yuan Ching, Guan-Wei Chen & Chih-Chuan Pan. (2022) The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: A systematic review and updated meta-analysis of double-blind randomized controlled trials. Journal of Affective Disorders 306, pages 182-189.
Crossref
Crossref
María del Mar Arango-Posada, Ana Isabel Prada-Escobar, Carolina Marín-Hernández, Veronica Monsalve-Franco & Diana Restrepo-Bernal. (2022) Tratamiento Exitoso para la Depresión Grave con Riesgo Suicida en un Paciente Trasplantado de Corazón. Revista Colombiana de Psiquiatría.
Crossref
Crossref
Jing Wang, Yi Sun, Pan Ai, Victoria Cui, Hui Shi, Dongjiao An, Anshi Wu & Changwei Wei. (2022) The effect of intravenous ketamine on depressive symptoms after surgery: A systematic review. Journal of Clinical Anesthesia 77, pages 110631.
Crossref
Crossref
Ya-Nan Gao, Yong-Qian Zhang, Hao Wang, Yu-Lin Deng & Nuo-Min Li. (2022) A New Player in Depression: MiRNAs as Modulators of Altered Synaptic Plasticity. International Journal of Molecular Sciences 23:9, pages 4555.
Crossref
Crossref
Tony Sun & Dimitry Francois. (2022) Potential Synergy of Lithium and Ketamine in Treatment of Recurrent Major Depression. Psychiatric Annals 52:4, pages 170-172.
Crossref
Crossref
Marion Voute, Thibault Riant, Jean‐Marie Amodéo, Gilbert André, Mario Barmaki, Olivier Collard, Caroline Colomb, Christelle Créac’h, Rodrigue Deleens, Claire Delorme, Géraldine de Montgazon, Véronique Dixneuf, Lénaïg Dy, Jacques Gaillard, Christian Gov, Xavier Kieffer, Michel Lanteri‐Minet, Jean‐Marie Le Borgne, Franck Le Caër, Fadel Maamar, Caroline Maindet, Fabienne Marcaillou, Frédéric Plantevin, Yves‐Marie Pluchon, Bruno Rioult, Sylvie Rostaing, Eric Salvat, Virith Sep Hieng, Marc Sorel, Pascale Vergne‐Salle, Véronique Morel, Ingrid de Chazeron & Gisèle Pickering. (2022) Ketamine in chronic pain: A Delphi survey. European Journal of Pain 26:4, pages 873-887.
Crossref
Crossref
Seonghoon Kim, Jihun Kang, Jongsoon Choi & Eunhee Kong. (2022) The effects of ketamine on pain control in stage IV cancer patients receiving palliative care. Kosin Medical Journal 37:1, pages 37-45.
Crossref
Crossref
Carolina Sepulveda Ramos, Matthew Thornburg, Kelly Long, Kiran Sharma, Julia Roth, Diana Lacatusu, Reece Whitaker, Daniel Pacciulli, Sulma Moredo Loo, Mohammad Manzoor, Yun-Yee Tsang, Sydney Molenaar, Karthikeyan Sundar & Robin J Jacobs. (2022) The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review. Cureus.
Crossref
Crossref
Weicheng Li, Yanling Zhou, Weijian Liu, Chengyu Wang, Xiaofeng Lan, Zhipei Zhang, Fan Zhang, Yanxiang Ye, Haiyan Liu, Kai Wu, Roger S. McIntyre & Yuping Ning. (2022) Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar depression: A naturalistic follow-up study. Journal of Affective Disorders 300, pages 172-178.
Crossref
Crossref
Bin Deng, Daowei Yang, Huanghui Wu, Lu Wang, Rui Wu, Hongrui Zhu, Ailing Huang, Jingyi Song, Tieliang Cai, Shanshan Liu, Jingsi Wu, Huiying Zhou & Chunhui Li. (2022) Ketamine inhibits TNF-α-induced cecal damage by enhancing RIP1 ubiquitination to attenuate lethal SIRS. Cell Death Discovery 8:1.
Crossref
Crossref
Chia-Ling Yu, Chih-Sung Liang, Fu-Chi Yang, Yu-Kang Tu, Chih-Wei Hsu, Andre F. Carvalho, Brendon Stubbs, Trevor Thompson, Chia-Kuang Tsai, Ta-Chuan Yeh, Szu-Nian Yang, Jae Il Shin, Che-Sheng Chu, Ping-Tao Tseng & Kuan-Pin Su. (2022) Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis. Journal of Clinical Medicine 11:4, pages 938.
Crossref
Crossref
Wm Maurice Redden, Saif-Ur-Rahman Paracha & Quratulanne Sheheryar. (2022) Hallucinogen Use and Misuse in Older Adults. Clinics in Geriatric Medicine 38:1, pages 55-66.
Crossref
Crossref
Callum J. Young, David Lyons & Hugh D. Piggins. (2022) Circadian Influences on the Habenula and Their Potential Contribution to Neuropsychiatric Disorders. Frontiers in Behavioral Neuroscience 15.
Crossref
Crossref
Georgios Mikellides, Panayiota Michael, Lilia Psalta, Teresa Schuhmann & Alexander T. Sack. (2022) A Retrospective Naturalistic Study Comparing the Efficacy of Ketamine and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression. Frontiers in Psychiatry 12.
Crossref
Crossref
Mary G Hornick, Margaret E Olson & Arun L Jadhav. (2022) SARS-CoV-2 Psychiatric Sequelae: A Review of Neuroendocrine Mechanisms and Therapeutic Strategies. International Journal of Neuropsychopharmacology 25:1, pages 1-12.
Crossref
Crossref
Meng Wu, Lin Zhao, Ye Wang, Qianqian Guo, Qi An, Jie Geng, Changsheng Zhang & Zhenggang Guo. (2022) Ketamine Regulates the Autophagy Flux and Polarization of Microglia through the HMGB1-RAGE Axis and Exerts Antidepressant Effects in Mice. Journal of Neuropathology & Experimental Neurology 81:11, pages 931-942.
Crossref
Crossref
Valentina Zonca. 2022. Encyclopedia of Behavioral Neuroscience, 2nd edition. Encyclopedia of Behavioral Neuroscience, 2nd edition
575
582
.
Edem Ekpenyong Edem, Collins-Kevin Chukwudi Anyanwu, Kate Eberechukwu Nebo, Elizabeth Toyin Akinluyi, Adedamola Adediran Fafure, Azeez Olakunle Ishola & Linus Anderson Enye. (2021) Ketamine abrogates sensorimotor deficits and cytokine dysregulation in a chronic unpredictable mild stress model of depression. Psychopharmacology 239:1, pages 185-200.
Crossref
Crossref
Nina Vindegaard Sørensen & Michael Eriksen Benros. 2023. Microorganisms and Mental Health. Microorganisms and Mental Health
15
34
.
Xiaoyu Zhang, Jianwei Wang, Xiao-Hu An, Yu-Chieh Chao, Yong Bian, Zifeng Xu & Tao Xu. (2021) Optimum dose of spinal ropivacaine with or without single intravenous bolus of S-ketamine during elective cesarean delivery: a randomized, double-blind, sequential dose-finding study. BMC Pregnancy and Childbirth 21:1.
Crossref
Crossref
Win Lee Edwin Wong, Gavin Stewart Dawe & Allan H. Young. (2021) The putative role of the relaxin-3/RXFP3 system in clinical depression and anxiety: A systematic literature review. Neuroscience & Biobehavioral Reviews 131, pages 429-450.
Crossref
Crossref
Paul F. White. (2021) Ketamine and depression: An old drug in search of a clinical indication. Journal of Clinical Anesthesia 75, pages 110500.
Crossref
Crossref
Mu-Hong Chen, Hui-Ju Wu, Cheng-Ta Li, Wei-Chen Lin, Shih-Jen Tsai, Chen-Jee Hong, Pei-Chi Tu, Ya-Mei Bai, Wei-Chung Mao & Tung-Ping Su. (2021) Low-dose ketamine infusion for treating subjective cognitive, somatic, and affective depression symptoms of treatment-resistant depression. Asian Journal of Psychiatry 66, pages 102869.
Crossref
Crossref
Jeffrey J. Mojica, Eric S. Schwenk, Clinton Lauritsen & Stephanie J. Nahas. (2021) Beyond the Raskin Protocol: Ketamine, Lidocaine, and Other Therapies for Refractory Chronic Migraine. Current Pain and Headache Reports 25:12.
Crossref
Crossref
Caroline Ferreira Fratelli, Jhon Willatan Siqueira, Bruna Rodrigues Gontijo, Maurício de Lima Santos, Calliandra Maria de Souza Silva & Izabel Cristina Rodrigues da Silva. (2021) BDNF Genetic Variant and Its Genotypic Fluctuation in Major Depressive Disorder. Behavioural Neurology 2021, pages 1-16.
Crossref
Crossref
Karla Aketzalli Hernández-Contreras, Jorge Antonio Martínez-Díaz, María Elena Hernández-Aguilar, Deissy Herrera-Covarrubias, Fausto Rojas-Durán & Gonzalo Emiliano Aranda-Abreu. (2021) Depressive Neuropsychiatric Symptoms and Mild Cognitive Impairment as Part of the Diabetes Mellitus/Alzheimer's Disease Link. Revista Colombiana de Psiquiatría.
Crossref
Crossref
Lili Ying, Yuyan Chen, Zuoquan Zhong, Yajin Wu, Lufeng Hu & Congcong Wen. (2021) Effects of long-term alcohol exposure on the pharmacokinetic profiles of ketamine and norketamine in rats. Alcohol 96, pages 55-61.
Crossref
Crossref
Zhaoying Wang, Xiulan He, Kim Long Le Vo & Andrew G. Ewing. (2021) Electrochemical and Mass Spectrometric Measurement of Enhanced Intravesicular Catecholamine Content and Exocytotic Frequency at Subanaesthetic Ketamine Doses. Analysis & Sensing 1:4, pages 166-170.
Crossref
Crossref
Christopher Sikes-Keilp & David R. Rubinow. (2021) In search of sex-related mediators of affective illness. Biology of Sex Differences 12:1.
Crossref
Crossref
Mohamed Abdel-Bakky, Elham Amin, Tarek Faris & Ahmed Abdellatif. (2021) Mental depression: Relation to different disease status, newer treatments and its association with COVID-19 pandemic (Review). Molecular Medicine Reports 24:6.
Crossref
Crossref
Celia Isabel López-Lorente, Mo Awchi, Pablo Sinues & Diego García-Gómez. (2021) Real-time pharmacokinetics via online analysis of exhaled breath. Journal of Pharmaceutical and Biomedical Analysis 205, pages 114311.
Crossref
Crossref
Chaoli Huang, Yuanyuan Wang, Zifeng Wu, Jiali Xu, Ling Zhou, Di Wang, Ling Yang, Bin Zhu, Guiquan Chen, Cunming Liu & Chun Yang. (2021) miR-98-5p plays a critical role in depression and antidepressant effect of ketamine. Translational Psychiatry 11:1.
Crossref
Crossref
Igor Magaraggia, Zilla Kuiperes & Rudy Schreiber. (2021) Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach. Neurobiology of Learning and Memory 183, pages 107467.
Crossref
Crossref
Chung-Pin Hsieh, Shao-Tsu Chen, Mei-Yi Lee, Chieh-Min Huang, Hwei-Hsien Chen & Ming-Huan Chan. (2021) N, N-dimethylglycine Protects Behavioral Disturbances and Synaptic Deficits Induced by Repeated Ketamine Exposure in Mice. Neuroscience 472, pages 128-137.
Crossref
Crossref
Xiao-Yuan Jing, Yan Wang, Hua-Wei Zou, Zi-Lin Li, Ying-Juan Liu & Lai-Fu Li. (2021) mGlu2/3 receptor in the prelimbic cortex is implicated in stress resilience and vulnerability in mice. European Journal of Pharmacology 906, pages 174231.
Crossref
Crossref
Emily S. Miller, Allie Sakowicz, Archana Roy, Ann Wang, Amy Yang, Jody Ciolino, William A. Grobman, Katherine L. Wisner & Lynn M. Yee. (2021) Is peripartum magnesium sulfate associated with a reduction in postpartum depressive symptoms?. American Journal of Obstetrics & Gynecology MFM 3:5, pages 100407.
Crossref
Crossref
Eric S. Schwenk, Basant Pradhan, Rohit Nalamasu, Lucas Stolle, Irving W. Wainer, Michael Cirullo, Alexander Olson, Joseph V. Pergolizzi, Marc C. Torjman & Eugene R. Viscusi. (2021) Ketamine in the Past, Present, and Future: Mechanisms, Metabolites, and Toxicity. Current Pain and Headache Reports 25:9.
Crossref
Crossref
Emma Kopra, Valeria Mondelli, Carmine Pariante & Naghmeh Nikkheslat. (2021) Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review. Journal of Psychopharmacology 35:8, pages 934-945.
Crossref
Crossref
Samuel Kohtala & Tomi Rantamäki. (2021) Rapid‐acting antidepressants and the regulation of TrkB neurotrophic signalling—Insights from ketamine, nitrous oxide, seizures and anaesthesia. Basic & Clinical Pharmacology & Toxicology 129:2, pages 95-103.
Crossref
Crossref
Anees Bahji, Carlos A ZarateJrJr & Gustavo H Vazquez. (2021) Ketamine for Bipolar Depression: A Systematic Review. International Journal of Neuropsychopharmacology 24:7, pages 535-541.
Crossref
Crossref
Máira Tereza Talma Chírico, Mariana Reis Guedes, Lucas Gabriel Vieira, Thayane Oliveira Reis, Aline Maria dos Santos, Ana Beatriz Farias Souza, Iara Mariana Léllis Ribeiro, Sylvana I.S.R. Noronha, Katiane O. Nogueira, Laser Antonio Machado Oliveira, Fabiana Aparecida Rodrigues Gomes, Fernanda Cacilda Silva, Deoclécio Alves Chianca-Jr, Frank Silva Bezerra & Rodrigo Cunha Alvim de Menezes. (2021) Lasting effects of ketamine and isoflurane administration on anxiety- and panic-like behavioral responses in Wistar rats. Life Sciences 276, pages 119423.
Crossref
Crossref
Linda Xing Yu Liu, Marina Golts & Virginia Fernandes. (2021) Role of the Pharmacist in Managing Treatment-Resistant Depression: A Focus on Ketamine. Pharmacy 9:3, pages 118.
Crossref
Crossref
Chad R. Johnson, Brian D. Kangas, Emily M. Jutkiewicz, Gail Winger, Jack Bergman, Andrew Coop & James H. Woods. (2021) Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition. Journal of Pharmacology and Experimental Therapeutics 377:3, pages 336-345.
Crossref
Crossref
Idriss Ali Abdoulaye, Shan-shan Wu, Enkhmurun Chibaatar, Da-fan Yu, Kai Le, Xue-jin Cao & Yi-jing Guo. (2021) Ketamine Induces Lasting Antidepressant Effects by Modulating the NMDAR/CaMKII-Mediated Synaptic Plasticity of the Hippocampal Dentate Gyrus in Depressive Stroke Model. Neural Plasticity 2021, pages 1-17.
Crossref
Crossref
Véronique Morel, Marie-Eva Pickering, Jonathan Goubayon, Marguérite Djobo, Nicolas Macian & Gisèle Pickering. (2021) Magnesium for Pain Treatment in 2021? State of the Art. Nutrients 13:5, pages 1397.
Crossref
Crossref
Meiying Cui, Wanlin Dai, Jing Kong & Hongzhi Chen. (2021) Th17 Cells in Depression: Are They Crucial for the Antidepressant Effect of Ketamine?. Frontiers in Pharmacology 12.
Crossref
Crossref
Tapan ParikhJohn T. Walkup. (2021) The Future of Ketamine in the Treatment of Teen Depression. American Journal of Psychiatry 178:4, pages 288-289.
Crossref
Crossref
Samuel Kohtala. (2021) Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacological Reports 73:2, pages 323-345.
Crossref
Crossref
Upinder Kaur, Bhairav Kumar Pathak, Amit Singh & Sankha Shubhra Chakrabarti. (2019) Esketamine: a glimmer of hope in treatment-resistant depression. European Archives of Psychiatry and Clinical Neuroscience 271:3, pages 417-429.
Crossref
Crossref
Fabio Lopes Rocha, Ulisses Gabriel de Vasconcelos Cunha, Roberta Campos Paschoalin, Cláudia Hara & Débora Pereira Thomaz. (2020) Use of subcutaneous ketamine to rapidly improve severe treatment-resistant depression in a patient with Alzheimer’s disease. International Clinical Psychopharmacology 36:2, pages 104-105.
Crossref
Crossref
Esmé Jansen van Vuren, Stephan F. Steyn, Christiaan B. Brink, Marisa Möller, Francois P. Viljoen & Brian H. Harvey. (2021) The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment. Biomedicine & Pharmacotherapy 135, pages 111200.
Crossref
Crossref
Guy A. Higgins, Nicole K. Carroll, Matt Brown, Cam MacMillan, Leo B. Silenieks, Sandy Thevarkunnel, Julia Izhakova, Lilia Magomedova, Ines DeLannoy & Edward M. Sellers. (2021) Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property. Frontiers in Pharmacology 12.
Crossref
Crossref
Linghong Chen, Yuting Ke, Hong Ma, Lei Gao, Yiying Zhou, Huaqiang Zhu, Huifen Liu, Fuqiang Zhang & Wenhua Zhou. (2021) Fluoxetine and Ketamine Reverse the Depressive but Not Anxiety Behavior Induced by Lesion of Cholinergic Neurons in the Horizontal Limb of the Diagonal Band of Broca in Male Rat. Frontiers in Behavioral Neuroscience 15.
Crossref
Crossref
Sari Goldstein Ferber, Aron Weller, Gal Yadid & Alexander Friedman. (2021) Discovering the Lost Reward: Critical Locations for Endocannabinoid Modulation of the Cortico–Striatal Loop That Are Implicated in Major Depression. International Journal of Molecular Sciences 22:4, pages 1867.
Crossref
Crossref
Zhiqing Zhan, Xichao Wang, Qing Chen, Zhidai Xiao & Bin Zhang. (2021) Comparative efficacy and side-effect profile of ketamine and esketamine in the treatment of unipolar and bipolar depression: protocol for a systematic review and network meta-analysis. BMJ Open 11:2, pages e043457.
Crossref
Crossref
Kristoffer A. A. Andersen, Robin Carhart‐Harris, David J. Nutt & David Erritzoe. (2020) Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies. Acta Psychiatrica Scandinavica 143:2, pages 101-118.
Crossref
Crossref
Nicole L. Galvão-Coelho, Wolfgang Marx, Maria Gonzalez, Justin Sinclair, Michael de Manincor, Daniel Perkins & Jerome Sarris. (2021) Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology 238:2, pages 341-354.
Crossref
Crossref
Avi A Weinbroum. (2021) Perspectives of Ketamine Use in COVID-19 Patients. Journal of Korean Medical Science 36:4.
Crossref
Crossref
Sagar Jilka, Clarissa Mary Odoi, Emma Wilson, Sazan Meran, Sara Simblett & Til Wykes. (2021) Ketamine treatment for depression: qualitative study exploring patient views. BJPsych Open 7:1.
Crossref
Crossref
Karen Lascelles, Lisa Marzano, Fiona Brand, Hayley Trueman, Rupert McShane & Keith Hawton. (2020) Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences. BJPsych Open 7:1.
Crossref
Crossref
Anees Bahji, Gustavo H. Vazquez & Carlos A. ZarateJrJr. (2021) Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Journal of Affective Disorders 278, pages 542-555.
Crossref
Crossref
Anees Bahji, Gustavo H. Vazquez, Elisa M. Brietzke & Carlos A. Zarate. 2021. Ketamine for Treatment-Resistant Depression. Ketamine for Treatment-Resistant Depression
117
129
.
Walter S. Marcantoni, Bertine Sandra Akoumba, Maggy Wassef, Julie Mayrand, Hinatea Lai, Stéphane Richard-Devantoy & Sylvie Beauchamp. (2020) A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 – January 2019. Journal of Affective Disorders 277, pages 831-841.
Crossref
Crossref
Jon Y. Zhou, Perry Hamilton, Stephen Macres, Matthew Peña & Schirin Tang. (2020) Update on Ketamine. Advances in Anesthesia 38, pages 97-113.
Crossref
Crossref
Ricardo Jorge Dinis-Oliveira & Teresa Magalhães. (2020) Abuse of Licit and Illicit Psychoactive Substances in the Workplace: Medical, Toxicological, and Forensic Aspects. Journal of Clinical Medicine 9:3, pages 770.
Crossref
Crossref
Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, Atul Khullar, Mary-Anne MacKay, Glen B. Baker & Serdar M. Dursun. (2020) Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Therapeutic Advances in Psychopharmacology 10, pages 204512532091665.
Crossref
Crossref